Marketing-authorisation holder · Canada
Kye Pharmaceuticals Inc.
17 medicines in 1 country, as authorisation holder.
Medicines
Every medicine in the registers under its name, current ones first.
17 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ACCRUFER30 mg · Capsule | Iron | Canada | Marketed | 2025 |
| AGAMREE40 mg / ml · Suspension | Vamorolone | Canada | Marketed | 2026 |
| CORZYNA750 mg · Tablet (Extended-Release) | Ranolazine | Canada | Authorised | |
| CORZYNA500 mg · Tablet (Extended-Release) | Ranolazine | Canada | Marketed | 2021 |
| CORZYNA375 mg · Tablet (Extended-Release) | Ranolazine | Canada | Authorised | |
| CORZYNA1000 mg · Tablet (Extended-Release) | Ranolazine | Canada | Marketed | 2023 |
| DYANAVEL XR20 mg · Tablet (Extended-Release) | Amfetamine | Canada | Marketed | 2026 |
| DYANAVEL XR15 mg · Tablet (Extended-Release) | Amfetamine | Canada | Marketed | 2026 |
| DYANAVEL XR10 mg · Tablet (Extended-Release) | Amfetamine | Canada | Marketed | 2026 |
| DYANAVEL XR2.5 mg / ml · Suspension (Extended-Release) | Amfetamine | Canada | Authorised | |
| DYANAVEL XR5 mg · Tablet (Extended-Release) | Amfetamine | Canada | Marketed | 2026 |
| FIRDAPSE10 mg · Tablet | Amifampridine | Canada | Marketed | 2020 |
| KYE-ESCITALOPRAM15 mg · Tablet | Escitalopram | Canada | Marketed | 2021 |
| QUILLIVANT ER CHEWABLE TABLETS30 mg · Tablet (Chewable Extended-Release) | Methylphenidate | Canada | Marketed | 2024 |
| QUILLIVANT ER CHEWABLE TABLETS20 mg · Tablet (Chewable Extended-Release) | Methylphenidate | Canada | Marketed | 2024 |
| QUILLIVANT ER CHEWABLE TABLETS40 mg · Tablet (Chewable Extended-Release) | Methylphenidate | Canada | Marketed | 2024 |
| QUILLIVANT ER ORAL SUSPENSION5 mg / ml · Powder (Extended-Release) | Methylphenidate | Canada | Marketed | 2024 |